News & Updates

Show Multimedia Only

Inhaled levodopa helps manage off episodes in PD, regardless of age

Treatment with the inhaled levodopa formulation CVT-301 provides rapid motor symptom relief during off periods, with consistent efficacy seen across Parkinson’s disease (PD) patients of all ages, according to a post hoc analysis of three phase III trials.

Inhaled levodopa helps manage off episodes in PD, regardless of age

a day ago

Tau-targeting therapy for early AD gets a pass to phase III

07 Aug 2026 by

In the phase II CELIA trial, the investigational tau-targeting antisense oligonucleotide (ASO) diranersen has shown therapeutic potential in patients with early Alzheimer’s disease (AD), yielding substantial reductions in tau burden and slowing clinical decline despite missing its primary endpoint.

Tau-targeting therapy for early AD gets a pass to phase III

07 Aug 2026

Cannabinoid combination quells agitation in late-stage dementia patients

05 Aug 2026 by

The experimental combination of tetrahydrocannabinol (THC) plus cannabidiol (CBD) proves beneficial in reducing agitation in hospice care-eligible patients with late-stage dementia, according to the phase II LiBBY trial.

Cannabinoid combination quells agitation in late-stage dementia patients

05 Aug 2026

SMA treatment with risdiplam: Experience in HK

05 Aug 2026 by

Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder that causes progressive muscle weakness and wasting, resulting in loss of motor function. The oral drug risdiplam demonstrated improvement or stabilization of motor function in clinical studies of patients with SMA. Professor Sophelia Chan of the Department of Paediatrics and Adolescent Medicine, University of Hong Kong, shared the latest published local findings on treatment outcomes with risdiplam in paediatric and adult patients with SMA.

SMA treatment with risdiplam: Experience in HK

05 Aug 2026

Prenatal ADHD medication use does not harm early developmental outcomes in offspring

04 Aug 2026

Children born to mothers with attention deficit/hyperactivity disorder (ADHD) who used associated medications during pregnancy do not seem to have adverse early childhood development, according to a retrospective study from the Netherlands.

Prenatal ADHD medication use does not harm early developmental outcomes in offspring

04 Aug 2026

Physical activity promotes long-term brain health

04 Aug 2026 by

Engaging in high levels of physical activity throughout adulthood may reduce the risk of dementia and preserve cognitive health.

Physical activity promotes long-term brain health

04 Aug 2026

Candesartan shows promise as first-line treatment for migraine

04 Aug 2026

Use of candesartan is both safe and effective, showing promise in the prevention of migraine headaches, suggests a study in the Philippines.

Candesartan shows promise as first-line treatment for migraine

04 Aug 2026

Resistance training lifts life quality in people with multiple sclerosis

04 Aug 2026 by

Individuals with multiple sclerosis may benefit from resistance training, which has been shown in a recent study to potentially improve quality of life (QoL), particularly in the domains related to physical and mental health.

Resistance training lifts life quality in people with multiple sclerosis

04 Aug 2026

Blood p-Tau217 levels prognostic of cognitive decline risk

04 Aug 2026 by

A large, multicohort study of cognitively unimpaired older adults has found that higher plasma p-tau217 levels are consistently associated with greater risk of progression to cognitive impairment and faster rates of cognitive decline, providing time-specific absolute risk estimates and supporting the potential of p-tau217 for prognostic model development.

Blood p-Tau217 levels prognostic of cognitive decline risk

04 Aug 2026

Elevated p-tau217 levels may help identify dementia risk early

03 Aug 2026 by

A pooled analysis presented at AAIC^® 2026 demonstrated a consistent association between higher levels of plasma phosphorylated tau 217 (p-tau217) and an increased risk of clinical progression and accelerated cognitive decline in a large cohort of older adults without cognitive impairment.

Elevated p-tau217 levels may help identify dementia risk early

03 Aug 2026

News & Updates

Showing Neurology articles

Showing

Specialty:

Inhaled levodopa helps manage off episodes in PD, regardless of age

Inhaled levodopa helps manage off episodes in PD, regardless of age

Tau-targeting therapy for early AD gets a pass to phase III

Tau-targeting therapy for early AD gets a pass to phase III

Cannabinoid combination quells agitation in late-stage dementia patients

Cannabinoid combination quells agitation in late-stage dementia patients

SMA treatment with risdiplam: Experience in HK

SMA treatment with risdiplam: Experience in HK

Prenatal ADHD medication use does not harm early developmental outcomes in offspring

Prenatal ADHD medication use does not harm early developmental outcomes in offspring

Physical activity promotes long-term brain health

Physical activity promotes long-term brain health

Candesartan shows promise as first-line treatment for migraine

Candesartan shows promise as first-line treatment for migraine

Resistance training lifts life quality in people with multiple sclerosis

Resistance training lifts life quality in people with multiple sclerosis

Blood p-Tau217 levels prognostic of cognitive decline risk

Blood p-Tau217 levels prognostic of cognitive decline risk

Elevated p-tau217 levels may help identify dementia risk early

Elevated p-tau217 levels may help identify dementia risk early